Cost-effectiveness of implant movement analysis in aseptic loosening after hip replacement: a health-economic model

被引:0
|
作者
Lovera, Davide [1 ,2 ]
Sandberg, Olof [2 ]
Mohaddes, Maziar [3 ,4 ]
Gyllensten, Hanna [5 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden
[2] Sectra, Linkoping, Sweden
[3] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Orthopaed, Gothenburg, Sweden
[4] Sahlgrens Univ Hosp, Gothenburg, Sweden
[5] Univ Gothenburg, Inst Hlth & Care Sci, Sahlgrenska Acad, POB 457, S-40530 Gothenburg, Sweden
关键词
Cost-effectiveness analysis; Cost and cost analysis; Arthroplasty; Replacement; Hip/adverse effects; Reoperation; Tomography; X-Ray computed; ARTHROPLASTY; ACCURACY;
D O I
10.1186/s12962-023-00498-w
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
ObjectiveTo investigate the cost-effectiveness of using Implant Movement Analysis (IMA) to follow up suspected aseptic loosening when the diagnosis after an initial X-ray is not conclusive, compared with a diagnostic pathway with X-ray follow-up.MethodsA health-economic model in the form of a decision tree was developed using quality-adjusted life years (QALY) from the literature, cost-per-patient data from a university hospital and the probabilities of different events from expert physicians' opinions. The base case incremental cost-effectiveness ratio (ICER) was compared with established willingness-to-pay thresholds and sensitivity analyses were performed to account for assumptions and uncertainty.ResultsThe base case ICER indicated that the IMA pathway was cost effective (SEK 99,681, compared with the SEK 500,000 threshold). In the sensitivity analysis, the IMA pathway remained cost effective during most changes in parameters. ICERs above the threshold value occurred in cases where a larger or smaller proportion of people receive immediate surgery.ConclusionA diagnostic pathway using IMA after an inconclusive X-ray for suspected aseptic loosening was cost effective compared with a pathway with X-ray follow-up.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis ofDAPA-HF
    McEwan, Phil
    Darlington, Oliver
    McMurray, John J. V.
    Jhund, Pardeep S.
    Docherty, Kieran F.
    Boehm, Michael
    Petrie, Mark C.
    Bergenheim, Klas
    Qin, Lei
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (11) : 2147 - 2156
  • [22] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN SPAIN
    Diamantopoulos, A.
    Forster, F.
    Brosa, M.
    Lees, M.
    Pinol, C.
    Febrer, L.
    VALUE IN HEALTH, 2008, 11 (06) : A533 - A533
  • [23] Cost-Effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada.
    Wells, Philip
    Diamantopoulos, Alexander
    Forster, Fiona
    Lees, Michael
    McDonald, Heather
    BLOOD, 2008, 112 (11) : 467 - 467
  • [24] COST-EFFECTIVENESS MODEL OF DUAL-MOBILITY CUPS FOR TOTAL HIP REPLACEMENT IN FRANCE
    Epinette, J. A.
    Robert, J.
    Rodriguez, J.
    Lafuma, A.
    VALUE IN HEALTH, 2014, 17 (07) : A381 - A381
  • [25] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT
    Vorobyev, P.
    Krasnova, L.
    Borisenko, O.
    Lukyantseva, D.
    Bashlakova, E.
    VALUE IN HEALTH, 2011, 14 (03) : A40 - A40
  • [26] Pitfalls in health-economic evaluations: the case of cost-effectiveness of prophylactic implantable cardioverter-defibrillator therapy in Belgium
    Van Brabandt, Hans
    Neyt, Mattias
    EUROPACE, 2009, 11 (12): : 1571 - 1573
  • [27] NICE HIPS: HIP REPLACEMENT INTERVENTIONS FOR OSTEOARTHRITIS IN THE UK - A CLINICAL AND COST-EFFECTIVENESS ANALYSIS
    Clarke, A.
    Pulikottil-Jacob, R.
    Grove, A.
    Freeman, K.
    Mistry, H.
    Tsertsvadze, A.
    Connock, M.
    Court, R.
    Ngianga-Bakwin, K.
    Costa, M.
    Sutcliffe, P.
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2014, 68 : A37 - A38
  • [28] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT OR TOTAL KNEE REPLACEMENT IN COLOMBIA
    Pereira, R.
    Duran, A.
    Lindner, L.
    Toro, W.
    Arango, C. H.
    VALUE IN HEALTH, 2009, 12 (07) : A502 - A502
  • [29] Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China
    Xiaoyu Yan
    Xiaohua Gu
    Zhenxing Xu
    Houweng Lin
    Bin Wu
    Advances in Therapy, 2017, 34 : 466 - 480
  • [30] COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT IN CHINA
    Yan, X. Y.
    Gu, X. H.
    Zhou, L.
    Lin, H. W.
    Wu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A866 - A866